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CHARLES HUGGINS
It is difficult to speak with scientific restraint of the contributions
of EdgarAllen tomankind. It is perhaps enough to saythat here in
New Haven the important school of anatomists, which knew his
influence, thrives with vigor, and that his work has profoundly
influenced biology universally, as will be apparent later in this
lecture.
Sexual maturity, in additiontoconferring certainbiological rights
and privileges, entails an increased susceptibility to neoplasms. If
any proof is needed, consider cancer of the breast which is exdusively
a disease of adult life where in man more than 99 per cent of the
cases occur in females."3 The relationship of tumors to the male sex
is well recognized also. Gastric cancer is slightly commoner in the
male13 19; among white males the death rate from cancer of the
buccal cavity was seven times that for white females,13 while cancers
of the lung, skin, and urinary bladder occur more than twice as
frequently in men as in women.
Maleness does notdiffer from femaleness in hormonesalone; the
occupation and habits of man enter into the causation of his diseases.
There is, however, a well-recognized androgenic hormonal com-
ponent operative in certain neoplasms. This will be discussed at
this time.
Beginning with the extraction of an estrogenic agent from the
ovaries of the hog 'by Allen and Doisy2 in 1923 numerous studies
have been made ofthe sex hormones and manyandrogenic substances
as well as estrogens have been isolated in acrystalline state; not only
has their chemical constitution 'been determined, but partial or com-
plete synthesis of most of them has been achieved. This work rep-
resents one of the greatest triumphs of science.
Androgen is a stimulant of growth causing certain areas to
increase in cell mass, the response representing the result of a
complex interplay of chemical agents acting on end-organs specific-
ally reactive to these forces. The responsive areas are most diversi-
fied and growth is strikingly observed, inter alia, in the integument
and its appendages, the musde, larynx, and the accessory sex struc-
tures. Areal hyperplasia is always of interest in the neoplastic
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prdblem, since the cancerous process is likewise a selective growth of
specific cellular areas.
The cells in which androgen causes growth are 'by definition the
secondary sexual characteristics of the constitutional male but these
agents also induce growth in the uterus1' and mammary ducts of the
female,4' 59, 65 these structures being responsive to both androgen and
estrogen. The effects of androgen on the uterus are particularly
marked in dogs (Figs. I and 2). The name androgen is, therefore,
terminologically inexact but despite its lack of precision it is con-
venient to retain, for want of a better, in studies of function.
The important feature of activity of the sex hormones seems to
be the action on tissues of specific atomic groups which profoundly
modify cellular functions, and the study of intramolecular spatial
relationships is beginning to be rewarding in this field. Schueler58
has postulated that a given structure may be estrogenic if it consists
of a rather large, rigid, and inert molecular structure with two active
hydrogen bond-forming groups, such as phenolic hydroxyl, located
at the optimum distanceof 8.55 A units from each other. However,
if the active groups are at a distance of approximately 9 to 10 A and
are somewhat weaker in hydrogen bond-forming character, for
example secondary alcoholic hydroxyl groups, the substance should
have androgenic activity. The dosage of the most active androgen
to produce characteristic effects is considerably larger than the quan-
tity of estrogen needed to produce estrus and this may be related to
the weaker hydrogen bond-forming power in the androgen.
Lacking as yet better characterization, androgen for technical
purposes is anythingwhich causesspecific growth ofcarefullydefined
areas, such as the comb ofthe capon ortall epithelium in the prostate
gland of mammals, regions which are not stimulated by most of the
agents which induce heat in mammals.
Androgen effects in cell chemistry
Although a great deal is known about what androgen does, very
little is known about how it exerts its effects, to wit:
1. Nitrogen retention. It has been shown that androgen pro-
duces a positive nitrogen balance in castrate dogs35' 36 and inman,33' 34
as well as a retention of phosphorus, sodium, and chloride. These
data are an indication that cell growth is occurring actively, but they
give no clue as to mechanism.
2. Colchicine studies. This technique was first applied in the
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study ofthe activity ofsex hormones by Allen, Smith, and Gardner,'
who found that the early growth response of the. cells of female
genital tissues to estrogen is restricted almost entirely to the epi-
thelium. It is now well known that colchicine causes scattering or
clumping of the chromosomes without spindle formation and this
arrest of cell division serves as an ind.ex of proliferation in tissues.
Burkhart7' 8 made single injections of androgen into castrate male
rats, estimating the effects on the ventral prostate by subsequent
administration ofcolchicine. Theearliest perceptible effect ofandro-
gen appears in the glandular epithelium 23 hours after injecting
testosterone propionate and consists ofan increase in cell mass. This
hypertrophycontinues and is followed at thethirty-fifth hour by cell
division.
3. Metabolic studies. Observations5 with the Warburg tech-
nique were made onslices ofprostatic tissue obtained before and after
orchiectomy in aseries ofdogs. The oxidative phase of carbohydrate
metabolism is appreciably decreased after androgen withdrawal, as is
indicated by a diminished oxygen uptake and pyruvate consumption
as well as by an increased aerobic glycolysis. It was concluded that
androgen takes part in the regulation of the oxidative metabolism of
prostatic tissue.
Androgenic effects on cell function
One of the interesting features of the neoplasm is its growth in
the fasting state-starvation does not cure cancer. Here, due to
some unknown growth stimulus, tumors increase actively when the
othertissues arewasting. Underthe influenceofandrogen, a growth
stimulus of known chemical constitution, the prostate grows con-
siderably and secretes at an exaggerated rate in food starvation,
5 and
by virtue of this compelling anaplastic force uses break-down prod-
ucts of other tissues for the growth ofan unessential structure during
a period ofpotential danger.
The secretoryactivityofthe prostaticgland maybe easilystudied
in dogs by the prostatic isolation operation" with subsequent assay of
secretion for long periods of time. The following four actions of
sex hormones on the prostatic function explain many of the effects of
androgen on tumor.
1. Orchiectomy causes a cessation of prostatic secretion in dogs
within from 7 to 23 days with concomitant epithelial atrophy.
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2. Androgen administration, for example testosterone propion-
ate 5 to 10 mg. dailydissolved in vegetable oil, restores the secretory
activity completely.
3. In a castrate dog appropriate doses of estrogen largely
vitiate27 the effect of injected androgen on the prostate. Diethyl-
stilbestrol, 0.1 mg. daily, stops the secretion of prostatic fluid in a
normal dog.
4. The primary effect of estrogen in abolishing prostatic sec-
tion is through androgen deprivation because of pituitary inhibition;
the injection of equine gonadotrophin simultaneously with effective
amounts of estrogen25 will restore the failing prostatic output after
estrogen alone has caused prostatic atrophy.
The prostate gland of dogs on casual examination seems to be a
simple structure, beingcomposed of asingle mass of tissue composed
of cells of uniform type. However, closer observation reveals25 that
the canine prostate is composed of two distinct functional units, the
dorsal and ventral segments. In the normal adult the epithelium of
both segments consists of tall columnar secretory cells. The differ-
entiation into segments is apparent only after estrogen therapy.
These two areas react differently to estrogen; the epithelium of the
dorsal segment is transformed to squamous cells by a threshold dose
of estrogen; the cells of the ventral segment never become so
modified.
This multiplicity ofstructure ofthe prostate is notconfined to the
dog. It has been known for some time that the anterior lobes of the
prostate of the rat and guinea-pig,867 68 and of the monkey"6 differ
from the remaining lobes in that they alone possess the power of
coagulating the secretion of the seminal vesicle of these species.
Canine prostatic fluid does not induce coagulation. Nevertheless,
the evidence for structural duality in the dog is dear cut.
The influence of androgen on tumors
The androgenic hormones bear three relationships to neoplastic
growth, namely, inhibition, stimulation, and no effect. Lack of
effect, being always of secondary scientific interest, will not be con-
sidered further here. The modifications of the activity of tumors
will be presented in the following eight cases where androgen
certainly exerts an influence
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In these four instances androgen inhibits the development of
neoplasms:
Case 1, Mammary cancer in the mouse. Nathanson and Ander-
vont52 found that the incidence of breast cancer in mice of the strain
C3H which had borne a litter was 100 per cent in the controls while
it was 30 per cent in similar mice injected with testosterone pro-
pionate, 0.5 mg., 3 times weekly. This reduced rate of incidence has
been confirmed for this32 and other mouse strains23 37 42 with high
incidence of breast cancer.
Case 2, Mammtary adenofibrona in the rat. Heiman and Kreh-
bid24 found that implantation ofthis tumor was followed by effective
takes in 33 per cent of intact males, in 66 per cent of females, and in
80 per cent of castrate males. It was observed also that estrogen
more than doubled the incidence of successful implants,2' while tes-
tosterone propionate22 in male and female rats reduced the number
of takes to about one quarter of the con-trols. Mohs'' 4 o_bserved
that androgen eliminated the epithelial elements of adenofibroma
although it did not inhibit the growth of the entire tumor.
Case 3, Uterine and abdominal fibroids in the guinea-pig. Lip-
schiutz and his pupils40' 4 observed that the action of estrogen in pro-
ducing these fibromyomata was blocked by testosterone, there
resulting either no tumor or only a little fibrosis or tumoral seed.
Case 4, Lymphoid tumors in mice and fowl. In most strains of
micewith a high leukemia incidence there is a greater rateofinvolve-
ment inthe femalethanin males; in the fowl, Marine and Rosen43' 4
had notobserved lymphomatosisoccurringin abird with spontaneous
comb growth. Now, Gardner'7 had discovered that estrogen was a
factor in producing lymphoid tumor of mice, and Gardner, Dough-
erty, and Williams'8 conducted an elaborate experiment revealing
androgenic inhibition ofthe development ofleukemia; in 822 control
mice the incidence of leukemia was 1.34 per cent, while in 1799 mice
injected with estrogen the incidence was 11.9 per cent. These
observers found that the administration of testosterone propionate
with estrogen in 378 mice reduced the incidence to 2.3 per cent. The
inducing action of estrogen was clearly inhibited by androgen.
In his strain of mice Murphy50 observed a high incidence of leu-
kemia in intact females and castrte males and females, while the
development of lymphoid tumors was apprecialbly lower in in-tact
males and in castrate females injected with androgen.
In Furth's laboratory45 gonadectomy in the female reduced the
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incidence of leukemia in mice from 74 to 45 per cent, while in the
male it hadessentially noeffect.
In this single case androgen causes some neoplastic regression:
Case 5, Cancer of the human female breast. Ulrich64 admin-
istered testosterone acetate to a woman with mammary cancer and
observed regression ofedema oftheaxillawhich was-believed to have
been caused by metastasis. Loeser42 treated three women having
metastatic mammary cancer with implantation of large amounts of
testosterone. While two of the cases were stated to have had tem-
porary improvement in general health and there was regression of
the tumor in one, the progress of the cancer was stated to have been
unaltered. Fels"6 treated three women with androgen; in one case
there was some regression of lymph nodes which were the site of
metastasis and in the others there was decrease of pain and some
improvement of general health. Adair and Herrmann' administered
androgen in large doses and concluded that in certain cases it may
effect a beneficial influence on patients with mammary cancer. In
their series of eleven patients four exhibited a favorable response to
testosterone propionate, 2 to 4 gm. administered within two to three
months; in one of the women there was regression of the primary
tumor as well as the soft part metastasis, while in three cases there
was an increased calcification of osteolytic lesions with a concomitant
disappearance of pain.
Farrow and Woodard16 treated 33 patients with testosterone pro-
pionate for brief periodls; about one-half of the cases obtained relief
of pain, but there were no other clinical or radiological indications
of improvement. In three cases androgen administration was fol-
lowed by an ,elevation of the calcium content of the serum associated
with absorption in the osseous metastasis.
In these three instances androgen stirmulates tumor growth:
Case 6, Ovarian cancer in the mouse. Strong and his
co-workers"1 transplanted this tumor in 168 females and in 153
males; all iof the males but only 8 females grew the tumor. In
castrate males the transplant took in 45 per cent of 31 mice but the
growth rate was less than in the intact male. Although the effects of
androgen injection were not reported the facts are best explained
through androgenic support of the host.
Case 7, Cancer of the prostate. It was shown in 1941 that
androgen caused an exacerbation of adlvanced prostatic cancer28 and
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conversely that anti-androgenic treatment frequently induced a clin-
ical remission3' which often was pronounced in degree. Estrogen
was thus the first agent of known chemical constitution to ameliorate
carcinomatosis in man and the only substance known at that time
which, when taken by mouth, influenced cancer beneficially.
The method of proof is sometimes of more interest than what is
proven; the first cobjective demonstration of the effects of hormones
on prostatic carcinoma was derived from a study of the phosphatases
of the blood which often reflected the improvement from the
decrease of androgenic activity. The benefit of androgen control,
however, was not limited tothe enzymes ofserum and often both the
primary lesion and the metastasis underwent more or less regression.
The remissions, although frequently of some magnitude, were fol-
lowed by a relapse before 5 years had elapsed in 80 per cent of the
first series of cases treated by orchiectomy; however four of these
original 20 patients who previously had extensive states of metastatic
malignant disease have no evidence of neoplastic activity on clinical
or chemical examination after periods varying from six to seven and
one-half years,26 the patients still beingunder observation.
In some of the cases of relapse after remission, the recrudescence
of disease is due to the elaboration of a functionally significant
amount of androgen26 in an extragonadal depot-the suprarenal
gland. This is believed tobe essentially the only source ofandrogen
besides the testis in the human male, because excision of the adrenals
and gonads in man30 eliminates theexcreton in the urine of materials
capable ofeffectingcombgrowth and also the urinary 17-ketosteroids
fall to very low levels.
In certain cases of prostatic cancer the tumor may be or may
become independent of androgen. This evidence is based on adren-
alectomy in a man who suffered a clinical relapse after the remission
of cancerous activity which followed orchiectomy. Life was sup-
ported for four months after suprarenalectomy30 by adrenal substi-
tutive therapy; yet in this case the cancer followed an unfavorable
course. In this relation bear in mind that in the normal male while
castration is followed by a marked decrease in prostatic size it does
not cause the epithelial cells oftheprostatetodisappear; they merely
shrink and remain functionally quiescent.
Case 8, Cancer of the human male breast. Farrow and Adair"4
administered testosterone propionate to a man with metastatic mam-
mary cancer and observed an increase in the number and extent of
the metastases, while bilateral orchiectomy was followed by clinical
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improvement. In the series of Treves63 there was partial regression
in 2 of 6 men with extensive breast cancer after excision ofthe testes.
Uncertain influence of androgen in neoplasms:
In the following three cases, uncertainty arises because the results
are unconfirmed or in controversy.
Case 9, Hepatomas. In mice of strain C3H Burns and Schen-
ken9 observed hepatomas in 27 per cent of breeding males, 7 per cent
of non-breeding males, and in no breeding females. They57 also
injected other mice of this strain with testosterone propionate and
with estrogens; androgen was reported to reduce the incidence of
hepatomas very much while estrogen increased it in the males.
Cantarow et al."0 injected esters of testosterone or estradiol in
rats ofthe Sherman strain which were also fed 2 acetamino-fluorene.
In the small series of animals reported, neoplasms were encountered
in 69 per cent of the estrogen series, 80 per cent of the androgen
group, and 29 percent ofthecontrols. Theauthorsthought that the
increased incidence may be related to the role of the liver in the
intermediary metabolism and excretion of the steroids.
Case 10, Brown-Pearce epithelioma. Murlin, Kochakian, Spurr,
andHarvey49inoculated this tumor intothetestes of rabbits,injecting
some of them with various steroids. Androgenic extracts from urine
and testosterone propionate inhibited the growth and metastasis of
thetumors.
Case 11, Transplantable tumors. Murphy and Sturm"' and
later Pribram54' 5 found that castration in male mice increased the
immunity to several types of transplantable tumors. Stewart6" and
Woglom69 observedl no effect of castration on the induction oftumors
in mice of C3H strain by 1: 2: 5: 6 dibenzathracene.
Discussion
The action of androgen on tumors is either to cause inhibition of
thedevelopment of aneoplasmortocause exacer'bation ofits growth.
Only in the single case of cancer of the breast in women does andro-
gen resultin regression oftheneoplasm.
It now remains to consider how far present knowledge of cell
function can explain the effects of androgen on malignancy.
The physiological neutralization of estrogen by androgen is a
quantitative competition ofthese steroids forcontrolofthe cell which
precisely resembles the metabolite inhibitors which have been studied
in a number of cases such as p-am-ino benzoic acid and the sulfon-
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amide type of drugs.58 The evidence for this similarity in the case
of androgen-estrogen antagonism is derived from their structural
resemblance and also from the fact that when these hormones are
present together in vivo the ratio between them determines which of
the variously acting steroids will have dominance; quantitatively
inhibition requires much greater amounts of one of the agents (sul-
fonamide, androgen) than of its antagonist (PABA, estrogen). To
this metabolite antagonism is ascribed the inhibition of the develop-
ment of tumors (cases 1-4) since the availability of the estrogen is
blocked by the androgen.
Not enough data are available todiscuss the furthering influences
of androgen on cancer of the breast in men or ovarian cancer in the
mouse wvithout an unreasonable amount of speculation.
In cancer of the breast of women one finds an extremely com-
plicated tumor in what, from an endocrine standpoint, is an extra-
ordinarily complex tissue. The mammary gland is stimulated by the
steroids, estrogen and progesterone; by the protein hormones, pro-
lactin and mammotrophin; and to a less extent by androgen and
desoxycorticosterone. c
Clinical improvement has been reported, and convincingly, in
breast cancer of human females from such widely divergent treat-
ment as ovarian excision and the administration of androgen or
estrogen.
Beatson' introduced ovariectomy as a treatment of advanced can-
cer of the breast, and beneficial results have been reported by many
workers12' 9who noted someregression ofthe disease. The artifical
menopause causes temporary regression or improvement62 in about
one-third of the cases with recurrent and inoperable carcinoma of the
breast, the most striking cases seeming to occur in those with osseous
metastasis.
Some inhibition has been observed in the estrogen therapy of
breast cancer of women. Haddow20 observed a significant, though
temporary, retardation of the tumoral growth by estrogenic treat-
ment in 10 of 22 patients, one of whom showed a prolonged arrest
of the tumor. That estrogen should cause this improvement is of
interest, since it has been firmly established that this agent is an
important factor in the causation of mammary cancers of mice.88
In four reports androgen treatment of breast cancer of women
has been stated to cause a lessening of pain, improvement of general
health, and in a few cases regression in the size of the neoplasms with
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increased calcification of the metastases. Farrow and Woodard,15
on the other hand, reported that while testosterone caus-ed relief of
pain in about one-half of their cases, there was evidence of increased
osteolytic activity of the metastasis in the bones and at times an
increased serum calcium. To complicate the issue further, testoster-
one, while inhibiting the developmen-t of mammary cancer in mice,
had no influence on established 'breast tumors.32' 52 Further, testos-
terone caused an exacerbation and orchiectomy produced a remission
in cancer of the human male breast.
This confused state of affairs makes it difficult to evaluate ameli-
orating effects on breast cancer of such divergent treatments as
androgen or estrogen or the removal of ovarian hormones by ovariec-
tomy. Although some regression seems to have resulted from all of
these measures, the impression is obtained that the endocrine treat-
ment of mammary cancer commonly is neither so great nor so
prolonged as occurs in the chemotherapy of other tumors such as
prostatic cancer, and that the percentage of reduction of man-pain
hours is less. More work is needed. We need to know the per-
centage of improvement and the duration of the remissions in larger
series. We needto know theactivity of the human pituitary in breast
cancer-knowledge which is now totally lacking, because the only
common physiological action of androgen and estrogen is hypo-
physeal depression. Above all, we need to know how the sex hor-
mones influence enzyme systems of normal and of malignant cells.
Fortunately the prostate gland is simpler than the breast endo-
crinologically, being affected directly by only two hormones,
androgen and estrogen. The stimulation of prostatic cancer by
androgen and the regression of the tumor whatever its locus in the
body byandrogen control is in exact line with the physiological effect
of this hormone on the mammalian prostate. Many of these pros-
tatic cancers are as highly dependent on androgen as is the normal
prostatic epithelium, while other neoplasms of this gland achieve
autonomy and thus become beyond control by the physiologic means
available at present.
Conclusion
Androgen has a profound effect on many neoplasms, ranging
from inhibition of the development of tumors to a stimulation of
cancerous growth. Many of the effects are explainable by present
knowledge of the physiological effects of androgen on cells. The
328ANDROGEN AND ANAPLASIA 329
anti-androgenic therapy of cancer of the prostate demonstrates that
a chemical change in the internal environment of the host may bring
about rapid and long-continued regression of a malignant epithelial
process.
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